

The effects of botulinum toxin A on patients with idiopathic detrusor overactivity. A double-blind, randomised, placebo-controlled trial.

Submission date
16/09/2005

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
19/10/2005

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
13/10/2009

Condition category
Urological and Genital Diseases

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Mohammad Shamim Khan

Contact details

Department of Urology
1st Floor Thomas Guy House
Guy's Hospital
London
United Kingdom
SE1 9RT

Additional identifiers

Protocol serial number

BOTOX Study Protocol

Study information

Scientific Title

Study objectives

Botulinum toxin A at 200 units will improve urinary frequency, urgency and incontinence episodes, urodynamic variables and quality of life compared with placebo.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double blind placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Overactive bladder symptoms and idiopathic detrusor overactivity.

Interventions

Baseline: voiding diary, urodynamics, quality of life (QoL) questionnaires.

Flexible cystoscopy and 3 bladder biopsies followed by injection of either 200 u of botulinum toxin A (20 injections at 10 u/ml/site) versus placebo (normal saline 20 injections at 1 ml/site).

Follow-up: At 4 and 12 weeks: urodynamics, voiding diary, flexible cystoscopy and 3 bladder biopsies, QoL questionnaires.

At 3 months patients are unblinded. Those that received placebo will be offered Botulinum toxin treatment.

Follow-up will be extended to confirm longevity of treatment. A further follow-up time point of 6 months will be instigated collecting the same data as at 4 and 12 weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Botulinum toxin A (Botox®)

Primary outcome(s)

1. Urinary frequency/24 hours
2. Maximum cystometric capacity

Key secondary outcome(s)

1. Urinary urgency/24 hours
2. Urge incontinence/24 hours
3. QoL: 3 validated QoL questionnaires (KHQ, UDI6, IIQ7)

4. Urodynamic variables:

- 4.1. time to first involuntary detrusor contraction
- 4.2. maximum detrusor pressure on filling/voiding
- 4.3. post void residual

Completion date

31/03/2006

Eligibility

Key inclusion criteria

1. Refractory to traditional anticholinergic therapy either due to poor efficacy or side effects
2. Proven detrusor overactivity on urodynamic studies
3. Detrusor overactivity of non-neurogenic origin

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnancy or planned pregnancy
2. Breast Feeding
3. Indwelling catheter
4. Current anticoagulation e.g. heparin or warfarin
5. Neurogenic detrusor overactivity
6. Painful bladder syndromes
7. Previous bladder surgery e.g. augmentation cystoplasty

Date of first enrolment

01/05/2004

Date of final enrolment

31/03/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Department of Urology
London
United Kingdom
SE1 9RT

Sponsor information

Organisation
Guy's and St Thomas' NHS Foundation Trust (UK)

ROR
<https://ror.org/00j161312>

Funder(s)

Funder type
Industry

Funder Name
British Urological Foundation (UK)

Funder Name
Allergan Ltd. (UK) - Unrestricted educational grant

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2009		Yes	No